ECTRIMS 2021: Key Takeaways, Data Highlights, and Ongoing Research

The 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), October 13-15, featured hundreds of presentations, conversations, and updates with experts in the care of patients with multiple sclerosis (MS). 

The virtual conference covered topics such as the use of integrative medicine (IM) in MS and the latest data for investigational agents, such as ATA188 in progressive MS, data on the efficacy and safety of ublituximab (TG Therapeutics), as well as results from a phase 2 study that evaluated autologous mesenchymal stromal cells secreting neurotrophic factors cells in patients with progressive MS. 

The NeurologyLive team sat down with several leaders in the MS field, learning more about key findings, while also gaining additional insight into areas for future research, the use of telehealth, and takeaways from ECTRIMS 2021 overall.

Click here for more coverage of multiple sclerosis from NeurologyLive, or for more coverage of ECTRIMS 2021, click here. 

REFERENCES

1. Connelly L, Fox M, Weigel M. Evaluation of a 6-week integrative medicine series on quality of life, self-efficacy, and wellness in MS. Presented at ECTRIMS Congress 2021; October 13-15; Virtual. Presentation 044. 
2. Bar-Or A, Pender MP, Hodgkinson SJ, et al. Updated open-label extension clinical data and new magnetization transfer ratio imaging data from a Phase I study of ATA188, an off-the-shelf, allogeneic Epstein-Barr virus-targeted T-cell immunotherapy for progressive multiple sclerosis. Presented at ECTRIMS Congress; October 13-15, 2021; Poster P638.
3. TG Therapeutics announces data for ublituximab in multiple sclerosis presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. News release. TG Therapeutics. October 14, 2021. Accessed October 14, 2021. https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-data-ublituximab-multiple-sclerosis
4. Cohen J, Lublin F, Lock C, Pelletier D, et al. Phase 2 safety and efficacy study of intrathecal MSC-NTF cells in progressive multiple sclerosis. Presented at ECTRIMS 2021.